Innovent Biologics and Jiangsu Aosaikang Pharmaceutical (ASK Pharm) have signed a strategic partnership agreement for the ...

Mok and colleagues hypothesized that first-line therapy with the EGFR inhibitor gefitinib would be at least as efficacious as carboplatin–paclitaxel chemotherapy in former smokers and light ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

The partners are preparing for commercialization of the lung cancer drug limertinib as they await an approval decision from China’s National Drug Administration.

We have gone through three generations of these TKIs. In the first generation were molecules like Erlotinib (Tarceva) and Gefitinib (Iressa), which were able to demonstrate high progression-free ...

or AZ’s Iressa (gefitinib). NICE has ruled that Tagrisso does not meet its end of life criteria, which allows for more flexibility in pricing, as existing drugs are doing enough to prolong ...

In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals ...

Approximately 213,380 new cases of non-small-cell lung cancer (NSCLC) were estimated to occur in the USA in 2007, which caused 160,390 NSCLC-related deaths. The majority of patients will be ...

Targeting EGFR, however, through tyrosine kinase inhibitors such as gefitinib and erlotinib 2 has a limited antitumor effect in breast cancer. Members of the type I receptor tyrosine kinase family ...

第三代EGFR TKI已经向大家展示这类药市场规模有多么可观：奥希替尼2015年获批上市，2023年总销售额已经达到57.99亿美元。在中国，奥希替尼、阿美替尼和伏美替尼三分天下之势已经成型，第三代EGFR ...

We have summarized in this article the current state of combination therapy of approved targeted drugs and irradiation. Since the introduction of the first targeted compounds almost (trastuzumab ...

将Gefitinib与LXH-3-71通过不同的化学连接子结合，筛选出最有效的EGFR降解剂——化合物37。随后，合成了针对CDK4的TPD分子45。实验结果显示，这些TPD ...